This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (403) Infectious Diseases (non-STD/STI) (1725)

Published on in Vol 12 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/41197, first published .
Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria

Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria

Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria

Authors of this article:

Brian D Foy1 Author Orcid Image ;   Anthony Some2 Author Orcid Image ;   Tereza Magalhaes3, 4 Author Orcid Image ;   Lyndsey Gray1 Author Orcid Image ;   Sangeeta Rao5 Author Orcid Image ;   Emmanuel Sougue2 Author Orcid Image ;   Conner L Jackson6 Author Orcid Image ;   John Kittelson6 Author Orcid Image ;   Hannah C Slater7 Author Orcid Image ;   Teun Bousema8 Author Orcid Image ;   Ollo Da2 Author Orcid Image ;   A Gafar V Coulidiaty2 Author Orcid Image ;   McKenzie Colt9 Author Orcid Image ;   Martina Wade9 Author Orcid Image ;   Kacey Richards9 Author Orcid Image ;   A Fabrice Some2 Author Orcid Image ;   Roch K Dabire2 Author Orcid Image ;   Sunil Parikh9 Author Orcid Image
Article Authors Cited by (6) Tweetations (17) Metrics

Journals

  1. Kaur B, Blavo C, Parmar M. Ivermectin: A Multifaceted Drug With a Potential Beyond Anti-parasitic Therapy. Cureus 2024 View
  2. Makuvara Z, Solomon R. Magano , Mugumbate G. Malaria situation and elimination in Africa with specific focus on Zimbabwe: a systematic review. Cogent Public Health 2024;11(1) View
  3. Dongmo F, Wondji C, Tsanou B, Djidjou-Demasse R. Quantifying ivermectin's optimal strategy impacts on malaria transmission: a dual-structured mathematical model. Applicable Analysis 2025;104(8):1526 View
  4. Somé A, Somé A, Sougué E, Ouédraogo C, Da O, Dah S, Nikièma F, Magalhaes T, Gray L, Finical W, Pugh G, Lado P, Randall J, Burton T, Ring M, Leon A, Colt M, Li F, Wang K, Wade M, Lier A, Richards K, Sproch H, Zhang E, Ellman J, Achebe I, Jackson C, Xiao M, Wu E, Bousema T, Slater H, Foy B, Parikh S, Dabiré R. Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial. The Lancet Infectious Diseases 2025;25(7):737 View
  5. Greenhalgh S, Roman A, Provencher A. Wonder drugs and where to use them: a forecast of ivermectin's impact on malaria in Africa. Infectious Disease Modelling 2025;10(4):1229 View
  6. Ouédraogo C, Somé F, Sagna A, Sougué E, Soma D, Ndiaye M, Coulibaly F, Pooda S, Zela L, Roberge C, Niang E, Mouline K, Dabiré R. Comparative susceptibility of wild and laboratory-reared Aedes and Anopheles larvae to ivermectin. Malaria Journal 2025;24(1) View